Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Acquired by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 143.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 200,470 shares of the company’s stock after purchasing an additional 118,118 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd owned 0.05% of Recursion Pharmaceuticals worth $1,355,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Victory Capital Management Inc. grew its position in shares of Recursion Pharmaceuticals by 25.1% in the 3rd quarter. Victory Capital Management Inc. now owns 27,394 shares of the company’s stock worth $181,000 after acquiring an additional 5,503 shares in the last quarter. Intech Investment Management LLC acquired a new position in Recursion Pharmaceuticals in the third quarter worth $349,000. Charles Schwab Investment Management Inc. increased its stake in Recursion Pharmaceuticals by 17.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after purchasing an additional 288,926 shares during the last quarter. Centaurus Financial Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the third quarter worth $71,000. Finally, Qsemble Capital Management LP acquired a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at about $224,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Down 3.2 %

Shares of Recursion Pharmaceuticals stock opened at $5.97 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.60 and a 1-year high of $12.36. The business’s fifty day moving average price is $7.46 and its two-hundred day moving average price is $7.00. The company has a market capitalization of $2.40 billion, a P/E ratio of -3.90 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.42) earnings per share. As a group, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Leerink Partners reduced their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.